TNF-α inhibitor therapy can improve the immune imbalance of CD4+ T cells and negative regulatory cells but not CD8+ T cells in ankylosing spondylitis.
Ankylosing spondylitis
CD4+ T cells
CD8+ T cells
Negative regulatory cells
TNF-α inhibitor
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
19 06 2020
19 06 2020
Historique:
received:
22
01
2020
accepted:
27
05
2020
entrez:
21
6
2020
pubmed:
21
6
2020
medline:
22
6
2021
Statut:
epublish
Résumé
Studies into ankylosing spondylitis (AS) and its relationship with immune imbalance are controversial, and the correlation between the efficacy of TNF-α inhibitor and changes in immune imbalance is unclear. A total of 40 immune cells were tested with flow cytometry, and the results of 105 healthy control (HC) subjects, 177 active-stage AS patients, and 23 AS cases before and after 12 weeks of TNF-α inhibitor therapy (Anbainuo) were analyzed. Compared with the HC group, the proportion of immune cells, such as naïve and central memory CD4+T cells, in AS increased (P < 0.0001), but effector memory and terminally differentiated CD4+T cells were decreased (P < 0.01 and 0.0001, respectively). Naïve, central memory, and effector memory CD8+T cells were increased (P < 0.0001, 0.001, and 0.01, respectively), but terminally differentiated CD8+T cells were decreased (P < 0.0001). Th1 cells (helper T cells-1), Tfh1 cells (follicular helper T cells-1), Tc1 cells (cytotoxic T cells-1), and Tregs (regulatory T cells) were lower (P < 0.01, 0.05, 0.0001, and 0.001, respectively), but Th17 cells, Tfh17 cells, and Tc cells were higher (P < 0.001, 0.0001, and 0.001, respectively). The proportions of total B cells and class-switched B cells were increased (P < 0.05), but non-switched B cells, plasma cells, memory B cells, and immature Bregs (regulatory B cells) were lower (P < 0.01, 0.0001, 0.0001, and 0.0001, respectively). After Anbainuo therapy, the percentage of naïve CD4+ T cells had decreased (P < 0.05) but Tregs and B10 cells (IL-10-producing regulatory B cells) had increased (P < 0.01 and 0.05, respectively), and the increase in Tregs was positively correlated with the decrease in C-reactive protein (CRP) (r = 0.489, P = 0.018). We found that active-stage AS patients have an immunity imbalance of frequency involving multiple types of immune cells, including CD4+T cells, CD8+T cells, Th cells, Tfh cells, Tc cells, Tregs, Bregs, and B cells. TNF-α inhibitor Anbainuo can not only help to inhibit disease activity but can also improve the immune imbalance of CD4+ T cells and negative regulatory cells in frequency. But CD8+ T cells have not been rescued.
Sections du résumé
BACKGROUND
Studies into ankylosing spondylitis (AS) and its relationship with immune imbalance are controversial, and the correlation between the efficacy of TNF-α inhibitor and changes in immune imbalance is unclear.
METHODS
A total of 40 immune cells were tested with flow cytometry, and the results of 105 healthy control (HC) subjects, 177 active-stage AS patients, and 23 AS cases before and after 12 weeks of TNF-α inhibitor therapy (Anbainuo) were analyzed.
RESULTS
Compared with the HC group, the proportion of immune cells, such as naïve and central memory CD4+T cells, in AS increased (P < 0.0001), but effector memory and terminally differentiated CD4+T cells were decreased (P < 0.01 and 0.0001, respectively). Naïve, central memory, and effector memory CD8+T cells were increased (P < 0.0001, 0.001, and 0.01, respectively), but terminally differentiated CD8+T cells were decreased (P < 0.0001). Th1 cells (helper T cells-1), Tfh1 cells (follicular helper T cells-1), Tc1 cells (cytotoxic T cells-1), and Tregs (regulatory T cells) were lower (P < 0.01, 0.05, 0.0001, and 0.001, respectively), but Th17 cells, Tfh17 cells, and Tc cells were higher (P < 0.001, 0.0001, and 0.001, respectively). The proportions of total B cells and class-switched B cells were increased (P < 0.05), but non-switched B cells, plasma cells, memory B cells, and immature Bregs (regulatory B cells) were lower (P < 0.01, 0.0001, 0.0001, and 0.0001, respectively). After Anbainuo therapy, the percentage of naïve CD4+ T cells had decreased (P < 0.05) but Tregs and B10 cells (IL-10-producing regulatory B cells) had increased (P < 0.01 and 0.05, respectively), and the increase in Tregs was positively correlated with the decrease in C-reactive protein (CRP) (r = 0.489, P = 0.018).
CONCLUSIONS
We found that active-stage AS patients have an immunity imbalance of frequency involving multiple types of immune cells, including CD4+T cells, CD8+T cells, Th cells, Tfh cells, Tc cells, Tregs, Bregs, and B cells. TNF-α inhibitor Anbainuo can not only help to inhibit disease activity but can also improve the immune imbalance of CD4+ T cells and negative regulatory cells in frequency. But CD8+ T cells have not been rescued.
Identifiants
pubmed: 32560733
doi: 10.1186/s13075-020-02226-8
pii: 10.1186/s13075-020-02226-8
pmc: PMC7304211
doi:
Substances chimiques
Anbainuo protein, human
0
Immunoglobulin Fc Fragments
0
Receptors, Tumor Necrosis Factor, Type II
0
Recombinant Fusion Proteins
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
149Références
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S47-58
pubmed: 22588768
Clin Exp Rheumatol. 2017 Sep-Oct;35(5):844-849
pubmed: 28421995
Rheumatology (Oxford). 2016 Feb;55(2):263-7
pubmed: 26350483
Nat Med. 2012 Jul 01;18(7):1069-76
pubmed: 22772566
Nat Rev Immunol. 2010 Jul;10(7):490-500
pubmed: 20559327
Arthritis Rheum. 1984 Apr;27(4):361-8
pubmed: 6231933
PLoS One. 2017 Jul 6;12(7):e0180726
pubmed: 28683133
Nature. 2014 Mar 20;507(7492):366-370
pubmed: 24572363
J Immunol. 2011 Feb 15;186(4):2672-80
pubmed: 21248258
Curr Rheumatol Rep. 2018 Apr 16;20(5):30
pubmed: 29663162
DNA Cell Biol. 2016 Feb;35(2):88-95
pubmed: 26556289
Life Sci. 2013 Nov 4;93(18-19):687-92
pubmed: 24044883
Sci Rep. 2016 Feb 10;6:20686
pubmed: 26861911
Int Immunol. 2015 Oct;27(10):479-86
pubmed: 26071023
J Immunol. 1999 May 1;162(9):5045-8
pubmed: 10227970
Rheumatol Int. 2003 Mar;23(2):61-6
pubmed: 12634937
Arthritis Res Ther. 2018 Aug 29;20(1):191
pubmed: 30157966
Exp Ther Med. 2015 Jan;9(1):250-256
pubmed: 25452811
Arthritis Rheumatol. 2016 Feb;68(2):494-504
pubmed: 26414243
Semin Immunol. 2014 Jun;26(3):183-90
pubmed: 24613728
Immunity. 2014 Dec 18;41(6):1040-51
pubmed: 25484301
Exp Ther Med. 2018 May;15(5):4578-4586
pubmed: 29731839
Gastroenterology. 2000 Feb;118(2):274-8
pubmed: 10648455
Genes Immun. 2017 Sep;18(3):135-143
pubmed: 28621304
Immunol Rev. 2020 Mar;294(1):27-47
pubmed: 31957051
Nat Rev Immunol. 2013 May;13(5):321-35
pubmed: 23618829
Medicine (Baltimore). 2019 Apr;98(15):e15094
pubmed: 30985663
Curr Allergy Asthma Rep. 2015 Jan;15(1):489
pubmed: 25447326
Clin Rheumatol. 2016 Sep;35(9):2175-83
pubmed: 27184046
Rheumatology (Oxford). 2018 Aug 1;57(suppl_6):vi4-vi9
pubmed: 30445483
Immunol Rev. 2010 Jan;233(1):181-202
pubmed: 20193000
Pathobiology. 2018;85(3):201-210
pubmed: 29212085
Immunol Lett. 2019 Nov;215:48-59
pubmed: 31442542
Biosci Trends. 2017 Mar 22;11(1):69-76
pubmed: 28179599
Immunol Cell Biol. 2016 Mar;94(3):293-305
pubmed: 26467610